Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease.

ABSTRACT:

Background

Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies. However, decreased patient acceptance and adherence to biosimilar medications have been reported, which can lead to loss of treatment response, adverse reactions, and inefficient resource utilization. Understanding patient perceptions of biosimilars and biosimilar switching is needed to inform patient-centered care strategies that promote efficient resource utilization.

Methods

We used democratic deliberation methods to solicit the informed and considered opinions of patients regarding biosimilar switching. Patients with infl

SUBMITTER: Ryan KA 

PROVIDER: S-EPMC11462922 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature